Trump crosses party lines to back Medicare drug-price negotiation

Alok Saboo Democratic presidential candidates Hillary Clinton and Bernie Sanders have already taken aim at pharma, talking up plans to give Medicare power to negotiate drug prices. ...

GSK, AstraZeneca and J&J back $57M effort to springboard university drug research

John Carroll Three of the U.K.'s leading universities are joining hands with three of the world's biggest pharma giants to create a new translational medicine group aimed at ...

Shire gets back on track with once-rejected eye drug

Damian Garde Shire has resubmitted the once-rejected eye treatment lifitegrast for FDA approval, handing in new data the company hopes will get its self-described blockbuster drug onto ...

China’s Cocoon rolls out a $720M fund to back U.K. biotechs; AbbVie teams up with MD Anderson on immuno-oncology;

Alok Saboo FierceBiotech News

Oncobiologics looks to a $115M IPO to back its biosimilars business

John Carroll Oncobiologics CEO Pankaj Mohan is turning to a turbulent public market to provide the next big injection of cash that will be needed to keep his knockoffs of Humira and ...

Post-restructuring, Biogen’s top execs are back in the R&D talent hunt

John Carroll SAN FRANCISCO–Four months after Biogen swiftly slashed 880 jobs in a wrenching restructuring, the biotech trendsetter is back on a new hiring spree in research aimed ...

Ysios, J&J back €11.5M round in Aelix to fund trials of HIV treatment

Nick Paul Taylor Aelix Therapeutics has raised €11.5 million ($ 12.6 million) to advance a therapeutic HIV candidate to clinical proof of concept. Ysios Capital, Johnson & ...

AstraZeneca walks back some of its immuno-oncology ambition

Damian Garde AstraZeneca, working to catch up with Merck and Bristol-Myers Squibb in the growing field of immuno-oncology, said its treatment is unlikely to win speedy approval in lung ...

Proxy advisers back Mylan’s Perrigo quest as investor vote looms

Carly Helfand Mylan hopes its shareholders vote in favor of its hostile bid for Ireland's Perrigo. And it got a boost on Wednesday that may help convince them to do so at a shareholder ...

With new cash on its way, it’s back to buying for deal-happy Allergan, CEO says

Carly Helfand On Monday, Allergan agreed to sell off a $ 40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. ...

Cost watchdogs back Novartis’ Xolair for big new market in chronic hives

Tracy Staton England's cost-effectiveness watchdogs have changed their mind on Xolair. The National Institute for Health and Care Excellence decided to back the Novartis asthma ...

Exclusive: Pfizer is once again cutting back R&D staff in reorganization

John Carroll Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS